Mayo Clinic
Rochester, Minnesota, 55905, United States
NCT Number: NCT00202696
To determine if nalmefene is safe and effective in smoking cessation.
Looking for future studies?
Notify Me25 year–65 year
All sexes
Interventional
Phase 2
Rochester, Minnesota, 55905, United States
Single centered, randomized, placebo-controlled,double-blind, outpatient pilot study to evaluate the efficacy, safety and tolerability of 2 doses of nalmefene on smoking cessation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
Looking for future studies?
Notify MeSomaxon Pharmaceuticals
Industry
A Single Center Evaluation of Nalmefene HCl Versus Placebo on Smoking Cessation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05004662
Behavior, Health Behavior
Tampa, Florida, United States
View Trial DetailsNCT06746025
Behavior, Behavior, Addictive
Naples, Florida, United States
View Trial DetailsNCT03714971
Behavior, Health Behavior
Izmir, Turkey (Türkiye)
View Trial DetailsNCT06909357
Behavior, Health Behavior
Coral Gables, Florida, United States
View Trial Details